Pfizer Inc Cdr Stock Probability Of Bankruptcy
| PFE Stock | 11.64 0.16 1.36% |
Pfizer |
Pfizer Inc CDR Company odds of distress Analysis
Pfizer's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Pfizer Probability Of Bankruptcy | Less than 9% |
Most of Pfizer's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pfizer Inc CDR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Pfizer probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Pfizer odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Pfizer Inc CDR financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Pfizer Inc CDR has a Probability Of Bankruptcy of 9.0%. This is 79.21% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all Canada stocks is 77.4% higher than that of the company.
Pfizer Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pfizer's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics of similar companies.Pfizer is currently under evaluation in probability of bankruptcy category among its peers.
Pfizer Fundamentals
| Return On Equity | 0.0906 | ||||
| Return On Asset | 0.0464 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 274.39 B | ||||
| Shares Outstanding | 16.7 B | ||||
| Price To Book | 1.60 X | ||||
| Price To Sales | 3.28 X | ||||
| Revenue | 63.63 B | ||||
| Gross Profit | 47.21 B | ||||
| EBITDA | 23.32 B | ||||
| Net Income | 8.03 B | ||||
| Total Debt | 6.95 B | ||||
| Book Value Per Share | 15.56 X | ||||
| Cash Flow From Operations | 12.74 B | ||||
| Earnings Per Share | 0.69 X | ||||
| Price To Earnings To Growth | 0.58 X | ||||
| Number Of Employees | 81 K | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 208.56 B | ||||
| Total Asset | 213.4 B | ||||
| Retained Earnings | 116.72 B | ||||
| Working Capital | 7.36 B | ||||
| Annual Yield | 0.07 % | ||||
| Net Asset | 213.4 B | ||||
| Last Dividend Paid | 1.68 |
About Pfizer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc CDR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc CDR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Pfizer
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pfizer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pfizer will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Pfizer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pfizer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pfizer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pfizer Inc CDR to buy it.
The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pfizer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pfizer Inc CDR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pfizer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Pfizer Stock
Pfizer financial ratios help investors to determine whether Pfizer Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pfizer with respect to the benefits of owning Pfizer security.